Atea Pharmaceuticals (AVIR) EBIT Margin (2021)

Atea Pharmaceuticals' (AVIR) quarterly EBIT Margin came in at 63.06% in Q4 2021, up 193.42% quarter-over-quarter from 67.5% in Q3 2021.

Atea Pharmaceuticals (AVIR) EBIT Margin (2021) Analysis & Trends

Atea Pharmaceuticals' EBIT Margin history runs 1 years deep, the most recent figure standing at 63.06% for Q4 2021.

On a quarterly basis, EBIT Margin changed N/A year-over-year to 63.06% in Q4 2021; TTM through Dec 2021 was 39.38%, a N/A change from a year earlier, with the FY2021 full-year figure at 39.38%, up 6206.0% from the prior year.
EBIT Margin advanced to 63.06% in Q4 2021 per AVIR's latest filing, from 67.5% in the prior quarter.
Across five years, EBIT Margin topped out at 63.06% in Q4 2021 and bottomed at 67.5% in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Atea Pharmaceuticals	376.19 Mn	376.19 Mn	-	-

Download Data